Supplementary Figures S1-S6 from Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth

PDF - 564 KB, Figure S1. Duodenal compound concentration profile of multiple compounds from a gastroduodenal passage simulation model; Figure S2. Kinetics of LY3023414 inhibition of PI3Kα; Figure S3. LY3023414 inhibition of mTORC1 in a concentration-dependent manner after ex vivo treatment of PMBC or whole blood; Figure S4. Activity of LY3023414 in a tumor clonogenic assay with a panel of patient-derived tumor xenografts passaged in nude mice and then grown in soft agar; Figure S5. Mean (±SD) concentrations of LY3023414 in male mice plasma, male rat plasma, and male beagle dog plasma following single dose; Figure S6. In vivo efficacy of LY3023414 and rapamycin alone and in combination using (A) H1975 and (B) 786-O xenograft tumor models.